Brief: Guerbet Announces ACR Committee Classified Elucirem Injection A Group II Agent

Guerbet SA

09/05/2023 13:35

May 9 (Reuters) - Guerbet SA  GRBT.PA :
    * GUERBET ANNOUNCES ACR COMMITTEE ON DRUGS AND CONTRAST
MEDIA
CLASSIFIES ELUCIREM™ (GADOPICLENOL) INJECTION A GROUP II AGENT
    * ANNOUNCED TODAY THAT BASED ON MOST RECENT SCIENTIFIC AND
CLINICAL EVIDENCE, ACR COMMITTEE ON DRUGS AND CONTRAST MEDIA HAS
CLASSIFIED ELUCIREM™ (GADOPICLENOL) AS A GROUP II AGENT.
    * ELUCIREM™ REQUIRES ONLY HALF GADOLINIUM DOSE OF
CONVENTIONAL
NON-SPECIFIC GBCAS, ADDRESSING PRACTITIONERS' CONCERNS ABOUT
GADOLINIUM EXPOSURE.
    * ELUCIREM™, A NOVEL NEW MACROCYCLIC GBCA FOR USE IN
CONTRAST-ENHANCED MAGNETIC RESONANCE IMAGING (MRI), HAS HIGHEST
RELAXIVITY COMPARED TO OTHER NON-SPECIFIC GBCAS
(GADOLINIUM-BASED CONTRAST AGENTS)

Source text for Eikon:  ID:nPn7r58ma 
Further company coverage:  GRBT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com ; +48 58 769 66 00;))